Tucatinib: tested in a combination
33 studies: another drug in the study is under test too. Page 1 of 1. Open to participants first (13), then studies with results posted, then the rest; newest registration first within each.
- Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast CancerRecruitingNCT07193394Phase 2Report a problem
- The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast CancerRecruitingNCT06439693Phase 2Report a problem
- Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 StudyRecruitingNCT06162559Phase 1Report a problem
- Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell CancerNot yet recruitingNCT06067776Phase 1Report a problem
- Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility StudyRecruitingNCT06016387Phase 2Report a problem
- Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast CancerRecruitingNCT05955170Phase 2Report a problem
- Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal DiseaseRecruitingNCT05800275Phase 2Report a problem
- Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast CancerRecruitingNCT05748834Phase 2Report a problem
- A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)RecruitingNCT05673928Phase 2Report a problem
- A Study of Tucatinib and Trastuzumab in People With Rectal CancerRecruitingNCT05672524Phase 2Report a problem
- Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)RecruitingNCT03297606Phase 2Report a problem
- TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerRecruitingNCT02693535Phase 2Report a problem
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingNCT01042379Phase 2Report a problem
- A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)Active, not recruitingNCT04721977Phase 2Results postedReport a problem
- A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of ResponseCompletedNCT04632992Phase 2Results postedReport a problem
- A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast CancerCompletedNCT04539938Phase 2Results postedReport a problem
- Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMDTerminatedNCT03501979Phase 2Results postedReport a problem
- Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast CancerTerminatedNCT05583110Phase 2Report a problem
- Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast CancerTerminatedNCT05553522Phase 1Report a problem
- Tucatinib+Trastuzumab+Eribulin in HER2+ MBCActive, not recruitingNCT05458674Phase 2Report a problem
- Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T StudyWithdrawnNCT05356897Phase 2Report a problem
- Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast CancerActive, not recruitingNCT05319873Phase 1/2Report a problem
- A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal CancerActive, not recruitingNCT05253651Phase 3Report a problem
- Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.Active, not recruitingNCT05230810Phase 1/2Report a problem
- Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer PatientsSuspendedNCT05062889Phase 2Report a problem
- Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast CancerActive, not recruitingNCT05041842Phase 2Report a problem
- Tucatinib With Chemotherapy and Trastuzumab in Advanced Her-2-neu Overexpressing, Previously Treated Breast Cancer.WithdrawnNCT04896320Phase 1/2Report a problem
- Tucatinib Together With Pembrolizumab and TrastuzumabTerminatedNCT04789096Phase 2Report a problem
- A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast CancerActive, not recruitingNCT04538742Phase 1/2Report a problem
- TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain MetastasesWithdrawnNCT04512261Phase 1/2Report a problem
- Tucatinib + Abemaciclib + Herceptin for HER2+ MBCWithdrawnNCT03846583Phase 1Report a problem
- A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib on MetforminCompletedNCT03826602Phase 1Report a problem
- A Study of ARRY-380 in Patients With Advanced HER2+ CancerCompletedNCT00650572Phase 1Report a problem